Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock
|
NLNK
|
The Nasdaq Stock Market
|
Exhibit Number
|
|
Description
|
99.1
|
|
Press Release, dated July 30, 2019, entitled "
NewLink Genetics Provides Corporate Update and Reports Second Quarter 2019 Financial Results
"
|
|
NewLink Genetics Corporation
|
|
|
|
|
By:
|
/s/ Carl W. Langren
|
|
Carl W. Langren
|
Its:
|
Chief Financial Officer
|
NewLink Genetics Corporation
|
|||||||||||||||
Consolidated Statements of Operations
|
|||||||||||||||
(unaudited)
|
|||||||||||||||
(In thousands, except share and per share amounts)
|
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2019
|
|
2018
|
|
2019
|
|
2018
|
||||||||
Operating Revenues:
|
|
|
|
|
|
|
|
||||||||
Grant revenue
|
$
|
—
|
|
|
$
|
1,884
|
|
|
$
|
—
|
|
|
$
|
11,268
|
|
Licensing and collaboration revenue
|
151
|
|
|
368
|
|
|
257
|
|
|
884
|
|
||||
Total operating revenues
|
151
|
|
|
2,252
|
|
|
257
|
|
|
12,152
|
|
||||
Operating expenses:
|
|
|
|
|
|
|
|
||||||||
Research and development
|
5,237
|
|
|
12,088
|
|
|
10,440
|
|
|
32,402
|
|
||||
General and administrative
|
5,638
|
|
|
7,912
|
|
|
11,205
|
|
|
16,204
|
|
||||
Total operating expenses
|
10,875
|
|
|
20,000
|
|
|
21,645
|
|
|
48,606
|
|
||||
Loss from operations
|
(10,724
|
)
|
|
(17,748
|
)
|
|
(21,388
|
)
|
|
(36,454
|
)
|
||||
Other income and expense:
|
|
|
|
|
|
|
|
||||||||
Miscellaneous (expense) income, net
|
(10
|
)
|
|
10
|
|
|
(5
|
)
|
|
34
|
|
||||
Interest income
|
624
|
|
|
461
|
|
|
1,248
|
|
|
846
|
|
||||
Interest expense
|
(24
|
)
|
|
(36
|
)
|
|
(25
|
)
|
|
(49
|
)
|
||||
Other income, net
|
590
|
|
|
435
|
|
|
1,218
|
|
|
831
|
|
||||
Net loss before taxes
|
(10,134
|
)
|
|
(17,313
|
)
|
|
(20,170
|
)
|
|
(35,623
|
)
|
||||
Income tax benefit
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Net loss
|
$
|
(10,134
|
)
|
|
$
|
(17,313
|
)
|
|
$
|
(20,170
|
)
|
|
$
|
(35,623
|
)
|
|
|
|
|
|
|
|
|
||||||||
Basic and diluted loss per share
|
$
|
(0.27
|
)
|
|
$
|
(0.47
|
)
|
|
$
|
(0.54
|
)
|
|
$
|
(0.96
|
)
|
|
|
|
|
|
|
|
|
||||||||
Basic and diluted average shares outstanding
|
37,276,443
|
|
|
37,165,529
|
|
|
37,275,954
|
|
|
37,160,334
|
|
NewLink Genetics Corporation
|
|||||||
Condensed Consolidated Balance Sheets
|
|||||||
(unaudited)
|
|||||||
(In thousands)
|
|||||||
|
|
||||||
|
June 30,
|
|
December 31,
|
||||
|
2019
|
|
2018
|
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
105,372
|
|
|
$
|
120,738
|
|
Prepaid expenses and other current assets
|
4,015
|
|
|
5,536
|
|
||
Income tax receivable
|
353
|
|
|
339
|
|
||
Other receivables
|
458
|
|
|
459
|
|
||
Total current assets
|
110,198
|
|
|
127,072
|
|
||
Property and equipment, net
|
3,314
|
|
|
3,727
|
|
||
Right-of-use asset
|
7,159
|
|
|
—
|
|
||
Income tax receivable
|
140
|
|
|
140
|
|
||
Total non-current assets
|
10,613
|
|
|
3,867
|
|
||
Total assets
|
$
|
120,811
|
|
|
$
|
130,939
|
|
Liabilities and Stockholders' Equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
689
|
|
|
$
|
555
|
|
Accrued expenses
|
7,235
|
|
|
8,139
|
|
||
Current portion of deferred rent
|
—
|
|
|
92
|
|
||
Current portion of lease liability
|
641
|
|
|
—
|
|
||
Current portion of notes payable
|
63
|
|
|
61
|
|
||
Total current liabilities
|
8,628
|
|
|
8,847
|
|
||
Long-term liabilities:
|
|
|
|
||||
Royalty obligation payable to Iowa Economic Development Authority
|
6,000
|
|
|
6,000
|
|
||
Notes payable
|
11
|
|
|
43
|
|
||
Lease Liability
|
7,485
|
|
|
—
|
|
||
Deferred rent
|
—
|
|
|
906
|
|
||
Total long-term liabilities
|
13,496
|
|
|
6,949
|
|
||
Total liabilities
|
$
|
22,124
|
|
|
$
|
15,796
|
|
Stockholders' equity:
|
|
|
|
||||
Blank check preferred stock, $0.01 par value: Authorized shares — 5,000,000 at June 30, 2019 and December 31, 2018; issued and outstanding shares — 0 at June 30, 2019 and December 31, 2018
|
—
|
|
|
—
|
|
||
Common stock, $0.01 par value: Authorized shares — 75,000,000 at June 30, 2019 and December 31, 2018; issued 37,413,093 and 37,343,547 at June 30, 2019 and December 31, 2018, respectively, and outstanding 37,300,960 and 37,251,220 at June 30, 2019 and December 31, 2018, respectively
|
373
|
|
|
373
|
|
||
Additional paid-in capital
|
410,946
|
|
|
407,199
|
|
||
Treasury stock, at cost: 112,133 and 92,327 shares at June 30, 2019 and December 31, 2018, respectively
|
(1,450
|
)
|
|
(1,417
|
)
|
||
Accumulated deficit
|
(311,182
|
)
|
|
(291,012
|
)
|
||
Total stockholders' equity
|
98,687
|
|
|
115,143
|
|
||
Total liabilities and stockholders' equity
|
$
|
120,811
|
|
|
$
|
130,939
|
|